HUTCHMED (China) Limited (HCM)

NASDAQ: HCM · Real-Time Price · USD

13.88

-0.21 (-1.49%)

At close: Sep 8, 2026, 4:00 PM EDT

13.83

-0.05 (-0.36%)

After-hours: Sep 8, 2026, 5:08 PM EDT

HUTCHMED (China) Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	549.12	548.51	630.2	838	426.41	356.13
Revenue Growth	0.11%	-12.96%	-24.80%	96.53%	19.73%	56.21%
Gross Profit	73.1	63.87	69.21	151.55	-271.59	-201.19
Operating Income	-34.78	-39.16	-43.71	18.38	-407.69	-328.32
Net Income	17.88	456.91	37.73	100.78	-360.84	-194.65
Earnings Per Share	0.02	0.52	0.04	0.12	-0.43	-0.25
EPS Growth	-96.12%	1200.03%	-66.28%	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Oncology/Immunology - Marketed Products	236.75	214.36	271.53	164.17	124.64	-
Oncology/Immunology - R&D	67.66	71.18	91.83	364.45	39.2	-
Other Ventures	244.71	262.97	266.84	309.38	262.57	236.52
Total	549.12	548.51	630.2	838	426.41	356.13

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	1,376	1,369	837.98	889.02	633.34	1,014
Total Debt	94.51	97.89	89.82	86.13	27.01	38.98
Net Cash (Debt)	1,282	1,271	748.16	802.88	606.33	975.48
Net Cash Growth	0.86%	69.89%	-6.82%	32.42%	-37.84%	142.21%
Net Cash Per Share	1.47	1.46	0.86	0.92	0.72	1.23

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	20.46	-64.66	0.5	219.26	-268.6	-204.22
Capital Expenditures	-10.51	-14.15	-17.93	-32.61	-36.66	-16.4
Free Cash Flow	9.95	-78.81	-17.44	186.65	-305.26	-220.62
Free Cash Flow Growth	-	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	13.31%	11.64%	10.98%	18.09%	-63.69%	-56.49%
Operating Margin	-6.33%	-7.14%	-6.93%	2.19%	-95.61%	-92.19%
Pretax Margin	3.66%	95.05%	7.20%	12.60%	-84.58%	-43.56%
Profit Margin	3.26%	83.30%	5.99%	12.03%	-84.62%	-54.66%
FCF Margin	1.81%	-14.37%	-2.77%	22.27%	-71.59%	-61.95%

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 8, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	134.30	5.27	66.65	30.53	-	-
P/FCF Ratio	241.40	-	-	16.48	-	-
PS Ratio	4.37	4.39	3.99	3.67	6.30	17.26